Hosted on MSN

VOR shares rally over 40% in pre-market trade after JPMorgan initiates bullish coverage

・Vor Biopharma shares surged over 40%after JPMorgan initiated coverage of the company. ・JPMorgan’s bullish stance comes amid Phase 3 clinical trial success for an autoimmune drug, telitacicept. ・On ...
Hosted on MSN

JP Morgan Initiates Coverage of Vor Biopharma (VOR) with Overweight Recommendation

Fintel reports that on December 9, 2025, JP Morgan initiated coverage of Vor Biopharma (NasdaqGS:VOR) with a Overweight recommendation. Analyst Price Forecast Suggests 388.04% Upside As of December 6, ...